CD8A and melanoma: 40 In a phase I clinical trial with a multivalent mRNA-based vaccine against melanoma, patients developed a strong response to different TAAs, and 75% of patients developed an immune response against at least one TAA, but most of them had a polyepitopic CD8+ T response.